Microfluidics-Prepared Uniform Conjugated Polymer Nanoparticles for Photo-Triggered Immune Microenvironment Modulation and Cancer Therapy

ACS Applied Materials & Interfaces
Zhe WangBin Liu

Abstract

Photothermal therapy (PTT) has shown great promise to spatiotemporally ablate cancer cells, and further understanding of the immune system response to PTT treatment would contribute to improvement in therapeutic outcomes. Herein, we utilize microfluidic technology to prepare biocompatible conjugated polymer nanoparticles (CP NPs) as PTT agents and assess the immune response triggered by CP-based PTT treatment in vitro and in vivo. Through careful control of the antisolvent, CP NPs with a uniform diameter of 52 nm were obtained. The c-RGD-functionalized CP NPs exhibit high photothermal conversion efficiency, inducing effective cancer cell death under an 808 nm laser illumination. Using macrophage cells as the model, CP NPs demonstrate effective activation of proinflammatory immune response. Furthermore, in tumor-bearing mice model, a single round of CP NP-assisted PTT could efficiently induce antitumor immunity activation and ultimately inhibit tumor growth. The study provides detailed understanding of both microfluidic technology for CP NP fabrication and photothermal-triggered antitumor immune responses.

References

Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·L R HirschJ L West
Jul 21, 2010·Nanoscale·Dönüs Tuncel, Hilmi Volkan Demir
Sep 16, 2010·AAPS PharmSciTech·Khushwant S Yadav, Krutika K Sawant
Oct 9, 2012·Nature Nanotechnology·Pedro M ValenciaRobert Langer
Nov 26, 2013·Advanced Drug Delivery Reviews·Nicolas BertrandOmid C Farokhzad
Feb 25, 2014·Nature Reviews. Cancer·Katrina F Chu, Damian E Dupuy
Aug 2, 2014·Nature Cell Biology·Sandra S McAllister, Robert A Weinberg
Sep 27, 2014·Chemical Reviews·Liang ChengZhuang Liu
Jan 24, 2015·Nature Reviews. Immunology·Takanori KitamuraJeffrey W Pollard
Aug 6, 2015·Chemical Reviews·Kenneth K Ng, Gang Zheng
Jan 17, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kanyi PuJianghong Rao
May 18, 2016·Nature Materials·Michelle S VezieJenny Nelson
Nov 1, 2016·Nature Nanotechnology·Saeid ZanganehHeike Elisabeth Daldrup-Link
Nov 9, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Juliana Cano-MejiaRohan Fernandes
Jan 25, 2017·Nature Reviews. Clinical Oncology·Alberto MantovaniPaola Allavena
May 30, 2017·Acta Pharmacologica Sinica·Cheng-Gen QianZhen Gu
Oct 17, 2017·Seminars in Immunology·Tamara G DacobaMaría José Alonso
Oct 17, 2017·Nature Biotechnology·Qingqing MiaoKanyi Pu
Feb 10, 2018·ACS Applied Materials & Interfaces·Tingting SunZhigang Xie
Apr 21, 2018·Biomacromolecules·Santhosh Kalash RajendrakumarIn-Kyu Park
Aug 4, 2018·Accounts of Chemical Research·Yuyan Jiang, Kanyi Pu
Sep 28, 2018·Chemical Society Reviews·Yijing LiuXiaoyuan Chen
Oct 3, 2018·Journal of Cellular Biochemistry·Masoud NajafiKeywan Mortezaee
Oct 6, 2018·Cell·Miguel F Sanmamed, Lieping Chen

❮ Previous
Next ❯

Citations

Jan 16, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Thais Fedatto AbelhaLea Ann Dailey
Oct 4, 2020·IET Nanobiotechnology·Hasnat Tariq, Syed Ali Imran Bokhari
Jun 3, 2021·Gels·Bibi Noorheen Haleema Mooneerah NeerooaSin-Yeang Teow
Mar 14, 2019·ACS Nano·Bing GuoBin Liu
Apr 10, 2020·Bioconjugate Chemistry·Qinglian Hu Bin Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.